Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06248671
PHASE2

Prophylactic Treatment With Atorvastatin for Episodic Migraine.

Sponsor: St. Olavs Hospital

View on ClinicalTrials.gov

Summary

The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.

Official title: EpisodicStatinMig. A Multicentre, Triple Blind, Placebo Controlled, Parallel Group Study of Atorvastatin in Episodic Migraine

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

450

Start Date

2024-05-01

Completion Date

2029-02-28

Last Updated

2026-02-19

Healthy Volunteers

Yes

Interventions

DRUG

Atorvastatin 40mg

Each tablet will be taken once daily for 84 days.

DRUG

Placebo

Each tablet will be taken once daily for 84 days

DRUG

Atorvastatin 20mg

Each tablet will be taken once daily for 84 days.

Locations (6)

Haukeland University Hospital

Bergen, Norway

University Hospital, Akershus

Lørenskog, Norway

Oslo University Hospital, Rikshospitalet

Oslo, Norway

Oslo University Hospital, Ullevål

Oslo, Norway

University Hospital Northern Norway

Tromsø, Norway

St. Olavs hospital

Trondheim, Norway